The Cardiac Biomarkers market is projected to surpass $100 billion by 2034, driven by the increasing burden of cardiovascular diseases, aging populations, and advancements in rapid diagnostic technologies. This growth indicates a significant positive impact on healthcare through improved diagnostics and potential for early intervention. Precautions involve ensuring equitable access to these advanced diagnostics and continued research to develop more accurate and cost-effective biomarkers.
